Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill

This article was originally published in The Tan Sheet

Executive Summary

FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.

Advertisement

Related Content

Guidance On Acetaminophen Allergy Warning Trails Industry's Change
Durbin’s DoD Supplement Proposal Could Be ‘Back Door’ To Pre-market Approval Rule
Industry News Roundup
Pay Now For Better Supplement Industry Enforcement, Or Foot Higher Bill Later
Pay Now For Better Supplement Industry Enforcement, Or Foot Higher Bill Later
In Brief: CHPA Disagrees With FDA Warning; Adulterated Supplements Enforcement; DASCA Support Sought
Hearing Targets OTC Eligibility For Health Savings Funds
Food Safety User Fees On Hold Until FDA Creates Waiver Process
CHPA Offers OTC Testing, Degradant Standards For Monograph Modernization
Durbin Bill Would Narrow Definition Of Dietary Supplement

Topics

Advertisement
UsernamePublicRestriction

Register

PS106535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel